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Background: Parasitaemia on Day 3 has been proposed as a useful alert of potential artemisinin resistance,
however, the normal variation of parasite clearance observed in artemisinin-based combination therapy clinical
trials is poorly documented.
Methods: The trends in early parasitological response following treatment with an artemisinin anti-malarial
regimen were reviewed. A PubMed literature search identified all studies using an artemisinin regimen for
uncomplicated falciparum malaria published between January 2000 and December 2011. Data from clinical
studies were extracted for analysis using a standardized questionnaire.
Results: In total 65,078 patients were enrolled into 213 clinical trials with 413 treatment arms containing either an
artemisinin derivative alone (n=26) or in combination with a partner drug (n=387). The proportion of patients
remaining parasitaemic at 24, 48 and 72 hours was documented in 115 (28%), 167 (40%) and 153 (37%) treatment
arms, respectively. Excluding resistance studies in Cambodia, the median proportion of patients still parasitaemic was
53.8% [range 3–95, IQR=30.5-69.2] on Day 1, 6% [range 0–65.9, IQR=2-11.5] on Day 2 and 0 [range 0–12.6, IQR=0-2]
on Day 3. Comparing studies from 2000 to 2005 and 2006 to 2011, the median proportion of patients reported to
remain parasitaemic at 72 hours decreased in Africa (1.2% vs 0%, p=0.007), but increased in Asia (0.4% vs 3.9%,
p=0.076). In 95% of studies the proportion of patients with peripheral parasitaemia was less than 6% at 72 hours.
Conclusions: These results highlight the normal distribution of early parasitological responses following ACT, and
the influence that heterogeneity in study design, host and parasite factors have in confounding a surveillance system
based on Day 3 parasite positivity. Greater understanding of factors influencing parasite clearance is crucial, but will
require analysis of pooled data from individual patient records.
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Artemisinin-based combination therapy (ACT) is currently
the first-line treatment for uncomplicated Plasmodium
falciparum malaria recommended by the World Health
Organization (WHO) [1]. Substantial decrease in malaria
attributable morbidity and mortality in some endemic
areas has been credited to the intensive deployment of
highly effective ACT treatment regimens and the wide-
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reproduction in any medium, provided the or(LLINs) [2]. However the continued success of these mal-
aria control programmes is under serious threat from the
emergence of artemisinin-resistant strains of P. falciparum
reported from the Thai-Cambodian border [3-5] and more
recently from the Thai-Myanmar border [6].
The artemisinin derivatives are the most potent anti-
malarial drugs, with a broad-stage specificity against
young ring-stage parasites, trophozoites and early game-
tocytes stages. The rationale behind ACT relies on the
high potency of artemisinin affecting a rapid reduction
in peripheral parasitaemia, thus reducing the parasite
biomass remaining to be eliminated by the longer-acting
partner drug [7]. Although the overall efficacy of ACT is. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Study profile.
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rates are predominantly a function of artemisinin activ-
ity. The hallmark of artemisinin resistance comes from
clinical observations of a delayed early clearance of de-
tectable parasitaemia in the peripheral blood film, asso-
ciated with an increase in parasite gametocyte and thus
transmissibility [3,4,6].
Surveillance of artemisinin resistance and delineation
of the boundaries of spread is critical if appropriate pub-
lic health measures are to be taken to contain or at least
delay the evolution of the process. As yet there are no
validated molecular markers of artemisinin resistance,
and current in vitro assays have proven insensitive at
identifying parasites associated with a clinical resistance
phenotype [8]. For this reason, surveillance strategies
have been devised to define resistance from the early
clearance of peripheral parasitaemia. A variety of param-
eters have been developed which vary in complexity as
well as sensitivity. Frequent sampling of the parasite
response and derivation of the rate of reduction has
been proposed as a reliable method for defining the
parasite susceptibility to artemisinin derivatives [9].
However such tests are logistically more difficult to
conduct than the current standard in vivo efficacy as-
sessment [10], and require appropriately designed pro-
spective application [11].
An alternative approach advocates the use of the pro-
portion of patients with detectable parasitaemia in a
blood smear taken on Day 3, 72 hours after starting
anti-malarial treatment [12]. When more than 10% of
patients have a detectable peripheral parasitaemia on
Day 3 this is considered to be indicative of suspected ar-
temisinin resistance. Such a definition is relatively simple
to implement and can be applied retrospectively from
completed clinical trials adhering to established WHO
guidelines on monitoring anti-malarial drug resistance,
providing a minimum of 50 patients have been enrolled
in the study [13]. However this simple approach is vul-
nerable to a number of important factors that may con-
found its interpretation.
In the current study the utility of applying a 10%
parasite positivity threshold on Day 3 as a marker of
artemisinin resistance, was reviewed from all available
published data from the last 12 years involving arte-
misinin derivatives. The objectives of the study were
to review the information currently available on para-
sitological measures of artemisinin-containing clinical
trials and to document early parasitological responses
to treatment.
Methods
Building the reference library
A systematic search of the literature was conducted to
identify all published antimalarial clinical efficacy studiesconducted since 1960. The key terms for the search are
presented in the additional files (see Additional file 1).
References were manually checked to confirm prospect-
ive clinical trials; these are available on the WWARN
website [14]. From this reference library all studies
assessing regimens containing an artemisinin derivative
between January 2000 and December 2011 were identi-
fied (see Additional file 2). Studies involving only non-
artemisinin regimen, pregnancy trials, longitudinal studies,
and studies of patients without P. falciparum infection
were excluded. The study profile generated by the search
algorithm is summarized in Figure 1.
Variables extracted
Each publication was reviewed and trial data extracted
to a standard record form. Variables included details on
the study location(s), randomization process, duration of
follow up, baseline characteristics, treatment given (in-
cluding dose and duration of artemisinin derivatives and
partner drugs), and parasite positivity rates (PPR) on
Day 1, 2 and 3 (see Additional files 3, 4 and 5).
Statistical analysis
Data were extracted and entered into Microsoft Office
Access™. All analyses were conducted using Stata soft-
ware, version 11.2 (StataCorp). The Mann–Whitney U
test or Kruskal-Wallis method were used for nonpara-
metric comparisons, and for categorical variables, pro-
portions were examined using Chi squared test with
Yates' correction or by Fisher's exact test. Logistic re-
gression model with a study random effect on individ-
ual patient data was used to determine the effect of
study characteristics (year, location, partner drug, arte-
misinin derivative, dose of artemisinin derivative) and
patient characteristics (age and parasite density) on
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of individual patient characteristics was investigated using
summary statistics reported in the publications and limita-
tions of this methodology have been previously reported
[15]. To maximize available data when the number of pa-
tients evaluated for parasitaemia was not stated in the text,
it was assumed that all patients in that study arm had been
evaluated at that time point. In the meta-analysis, propor-
tions were transformed using the Freeman-Tukey variant
of the arcsine square root transformation and random ef-
fects model using the method of DerSimonian & Laird,
with the estimates of heterogeneity derived from the
Mantel-Haenszel model [16,17].
Results
Between January 2000 and December 2011, 213 clinical
trials were identified in which a total of 65,078 patients
with uncomplicated falciparum malaria were enrolled
into 413 treatment arms containing an artemisinin de-
rivative (Figure 1). The median sample size per treatment
arm was 110 (range 10–1,475), with most of the data de-
rived from comparative drug trials (189, 89%), of which
177 (83%) were randomized trials. The remaining 24
(11%) studies were single-arm studies. The number of tri-
als published annually increased during the study period
from five publications in 2000 to a peak of 28 in 2009, al-
though numbers declined thereafter (Figure 2). Overall
37,192 (57%) patients had P. falciparum mono-infection
and 7,908 (12%) had mixed infections on admission. The
remaining 19,978 patients were enrolled in studies in
which parasite species was not stated; these were mostly
conducted in Africa. Follow up was continued for 28 days
in 134 (63%) studies, with 50 (24%) extending to 42 days,Figure 2 Temporal trends in publication of anti-malarial clinical trialsand 10 (5%) up to 63 days. The proportion of trials
with at least 42 days of follow up rose from 20% (15/74)
in the period between 2000 and 2005 to 36% (49/138)
between 2006 and 2011; p=0.027. The most frequent treat-
ment regimens reported were: artemether-lumefantrine
(AL, in 96 treatment arms), artesunate-mefloquine
(AS+MQ, N=75), artesunate-amodiaquine (AS+AQ,
N=74), artesunate-sulphadoxine-pyrimethamine (AS+SP,
N=43), and dihydroartemisinin-piperaquine (DHA+PIP,
N=40). In 26 treatment arms, patients received monother-
apy only, including either artesunate (N=17), dihydro-
artemisinin (N=1), artemisinin (N=3), beta-artemether
(N=2) and arterolane (N=3). Treatment was supervised
completely in 362 (90%) and partially in 30 (7.5%) of the
402 studies in which it this was documented.
The majority of studies came from Africa, which con-
tributed 131 (62%) studies and 43,982 (68%) patients.
There were 67 (31%) trials in Asia recruiting 18,083
(28%) patients and 11 studies from South America
recruiting 1,295 (2%) patients. Locations of these study
sites are presented in Figures 3, 4 and 5. A total of 21
multicentric trials (involving at least two countries) were
reported, 17 of which were conducted in Africa, three
trials in Asia and the other in South America. Two stud-
ies included sites in both continents. African trials were
more likely to recruit children (<14 years), with only 3%
(4/131) of trials enrolling adults; the median age
reported being four years (range 0.6-39.5). In contrast,
94% (63/67) of Asian studies enrolled adults with a me-
dian age of 24 years (range 2.9-38). The median baseline
parasitaemia reported was 22,905 μl-1 (range 2,700-
105,426) in African trials, compared to 8,986 μl-1 (range
536–65,299) in Asia (see Additional file 4).with an artemisinin-based combination therapy.
Figure 3 Map depicting location of artemisinin-based combination therapy clinical studies conducted in Africa since 2000. Coloured
icons denote number of studies at each site (yellow = 1; light orange = 2; dark orange = 3; red = >4).
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parasitaemia was 4,445 μl-1 (range 2,838-7,309) and the
median age at enrolment was 25.9 years (range 6.7-36).
Of the 1,295 patients recruited in South America, 59%
(762) received AS+MQ in 10 treatment arms, 20% (262)
were allocated to DHA+PIP, 12% (151) to AS+SP and the
remainder were treated by AL, AS+AQ or artesunate rec-
tal capsule.
Parasitologic response during the first three days
The early parasitological response to treatment was
reported in 60% (128/213) of studies, with the parasite
positivity stated (or derived) at Day 1 in 115 (28%)
treatment arms, at Day 2 in 167 (40%) treatment arms
and at Day 3 in 153 (37%) treatments arms. Most
studies (53% 113/213) assessed blood smear once daily,
but in 27% (58/213) of studies examination was morefrequent (four to 12 hourly). In 29 (14%) studies para-
sitaemia was reported less than once daily and the re-
mainder (13 studies) did not specify intervals of blood
slide taken in the methodology.
The proportion of patients with parasitaemia on Days 1,
2 and 3 and the median parasite positivity rates (PPR) de-
rived from studies are presented in Table 1, with individual
PPRs at Day 2 presented in Additional files 3 and 5).
Factors influencing early parasite responses
Parasite positivity rate at Day 1 (PPRday1) and Day 2
(PPRday2) did not differ between Asia and Africa, but
by Day 3 (PPRday3) patients from Asian studies were
at significantly greater risk of remaining parasitaemic
(Odds Ratio OR = 3.58 [95% CI 1.15 – 10.13]; p=0.027).
The proportion of patients with detectable parasit-
aemia depended significantly on the number of days in
Figure 4 Map depicting location of artemisinin-based combination therapy clinical studies conducted in Asia since 2000. Coloured
icons denote number of studies at each site (yellow = 1; light orange = 2; dark orange = 3; red = >4).
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administered. In Africa the OR [95% CI] for PPRday2
was 2.72 [1.90-3.92] for regimens with less than two days of
artemisinin derivative therapy (four arms with 588 patients)
and was 6.19 [3.43-11.17] for PPRday3 for treatments with
shorter than three days (nine arms with 1,370 patients)
compared to regimens with longer courses of artemisinin
derivatives. In Asia, all treatments included at least three
days of artemisinin derivatives, except for 182 patients
in two study arms who received only two days. Further
analyses of PPRday2 were restricted to patients who re-
ceived at least two days of artemisinin derivatives and
of PPRday3 to patients who received at least three days
of artemisinin derivatives.
In African studies, the median age of the patient was
associated with a reduced risk of parasitaemia at Day
1 (OR 0.97 [95% CI 0.95 - 0.99]), but not on subse-
quent days (Table 2). Increasing parasitaemia at pres-
entation was associated with a higher PPR on Day 1
(OR 1.74 [95% CI 1.26 -2.39]), Day 2 (OR 1.74 [95% CI
1.25 - 2.42]) and Day 3 (OR 2.68 [95% CI 1.00-7.18]),
for unit exponential increase). There was also a signifi-
cant difference in the parasite positivity rates betweentreatment regimens: patients treated with AL were
more likely to be parasitaemic than those treated with
DHA+PIP at both 24 hours (OR = 1.50 [95% CI 1.19 -
1.88]) and 48 hours (OR 1.70 [95% CI 1.21 -2.40]). Al-
though a similar difference was also noted for three-day
regimens of AS+SP and AS+AQ, this was only apparent
at 48 hours (OR 2.17 [95% CI 1.33-3.54] and OR 2.05
[95% CI 1.39-3.03], respectively).
In Asian studies, there were no significant differences
in initial parasite clearance between treatment regimens
at 48 or 72 hours (Table 3). However, increasing baseline
parasitaemia was associated with higher PPRday1 (OR
2.42 [95% CI 1.58-3.70]), PPRday2 (OR 3.11 [95% CI
1.86-5.20]) and PPRday3 (OR 8.20 [95% CI 3.97-16.97]
per unit exponential increase). This relationship remained
significant at 48 hours but not at 72 hours, when studies
from Cambodia, where artemisinin resistance has been
confirmed, were excluded.
In African studies, univariate factors were con-
firmed in multivariate analysis of parasitaemia at Day
1 and Day 2 (Table 4). After correcting for age, base-
line parasitaemia and year, patients treated with AL
(adjusted OR (AOR) 1.61 [95% CI 1.14-2.28]), AS+SP
Figure 5 Map depicting location of artemisinin-based combination therapy clinical studies conducted in Latin America since 2000.
Coloured icons denote number of studies at each site (yellow = 1; light orange = 2; dark orange = 3; red = >4).
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[95% CI 1.23-2.74]) were significantly more likely to be
parasitaemic at Day 2 compared to those receiving
DHA+PIP. At Day 3, there were no significant differences
between treatments.
In the multivariate analysis of the Asian studies,
baseline parasitaemia, age and treatment regimen also
remained significantly associated with delayed parasite
clearance (Table 5). After correcting for confounding
factors, treatment with AL (AOR = 1.81 [95% CI
1.42-2.31]) or AS+MQ (AOR = 1.40 [1.12-1.76]) was
associated with higher PPRday1 than treatment with
DHA+PIP. Patients treated with AL had higher PPRday1
than either AS+MQ (AOR=1.29 [1.01-1.65]) or AS+AQ
(AOR =2.72 [1.15-6.44]. At Day 2 and Day 3 the onlyfactor independently associated with parasite clearance was
baseline parasitaemia.
Temporal trends
In the studies conducted in Asia, there was a temporal
trend for an increased risk of parasite positivity at Day 1
(AOR = 0.90 [95% CI 0.81-0.99] per year), but not at
other time points. In African studies, the reverse was ob-
served, with a linear trend for decreased positivity at all
days, but only statistically significant on Day 1 and Day 3
(AOR= 0.84 [95% CI 0.73-0.96]; AOR = 0.78 [95% CI 0.62-
0.97] per year, respectively).
Temporal trends in parasitological response were
assessed in studies conducted from 2000 to 2005 and
compared with 2006 to 2011. In African studies, the
Table 1 Parasite positivity according to day of follow up and continent
Proportion of patients with patent parasitaemia Parasite positivity rate
Number of study arms Median % [Range,IQR]
Africa
Day 1 53.2% (6,694/12,576) 76 48.9% [Range: 2.6-94.4 IQR: 26.6-66.4]
Day 2 8.3% (1,575/19,044) 111 6.1% [Range: 0–65.9, IQR: 1.6-11.2 ]
7.9% (1,456/18,466) 107 6.0% [Range: 0–65.9, IQR: 1.6-11.0 ]
Day 3 1.0% (238/18,593) 115 0% [Range: 0–36.5, IQR: 0–1.2 ]
1.0% (176/17,223) 107 0% [Range: 0–10.0, IQR: 0–1.2 ]
Asia
Day 1 59.0% (2,794/4,733) 30 59.9% [Range: 0—84.3, IQR: 37.7-74.0]
59.5% (2,793/4,691) 28 61.6% [Range: 16.4—84.3, IQR: 41.1-74.0]
Day 2 12.2% (808/6,608) 45 8.9% [Range: 0–72.5, IQR: 3.3-20.8]
Day 3 3.8% (247/6,651) 45 1.1% [Range: 0–55.0, IQR: 0–5.3]
3.8% (243/6,399) 41 1.7% [Range: 0–55.0, IQR: 0–5.6]
South America
Day 1 39.6% (237/598) 5 48.0% [Range: 32.3-75.0, IQR=41.5-48.0]
Day 2 6.0% (43/719) 7 4.0% [Range: 0–21.4, IQR=1.1-17.9]
Day 3 1.0% (10/1044) 11 0% [Range: 0–8.6, IQR=0-2.1]
First row in each day category shows all reported results. The second row (if present) shows the results after exclusion of study arms with rectal artesunate and
with short (<1, 2 or 3 days, respectively) treatment with artemisinin derivatives.
Table 2 Univariate analysis of factors associated with early parasite response in Africa
Day 1 Day 2 Day 3
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Age 0.97 (0.95-0.99) 0.016 1.01 (0.97-1.04) 0.767 1.04 (0.96-1.12) 0.354
Loge parasitaemia 1.74 (1.26-2.39) 0.001 1.74 (1.25-2.42) 0.001 2.68 (1.00-7.18) 0.050
Year 0.88 (0.78-1.00) 0.051 0.89 (0.78-1.02) 0.087 0.79 (0.64-0.99) 0.039
Artemisinin derivative <0.001 0.002 0.141
Artemether 1.00 1.00 1.00
Artemisinin 0.87 (0.41-1.86) 0.718 NA NA
Artesunate 0.83 (0.72-0.95) 0.009 1.06 (0.84-1.34) 0.617 1.16 (0.56-2.41) 0.692
DHA 0.65 (0.51-0.83) <0.001 0.57 (0.40-0.80) 0.001 0.21 (0.02-1.79) 0.154
Treatment 0.002 0.004 0.494
DHA+PIP 1.00 1.00 1.00
AL 1.50 (1.19-1.88) 0.001 1.70 (1.21-2.40) 0.002 4.70 (0.55-40.03) 0.157
AS+MQ 1.34 (0.86-2.08) 0.19 2.25 (0.98-5.14) 0.055 6.03 (0.43-84.46) 0.182
AS+SP 1.08 (0.48-2.43) 0.851 2.17 (1.33-3.54) 0.002 7.60 (0.86-66.87) 0.067
AS+AQ 1.30 (0.98-1.73) 0.073 2.05 (1.39-3.03) <0.001 5.99 (0.74-48.64) 0.094
AS alone 0.73 (0.16-3.29) 0.685 0.76 (0.29-2.01) 0.583 ND1
Only patients who received artemisinin derivative until Day 1 (2 or 3) are included for analysis of Day 1 (2 or 3). Study arms with rectal artesunate were excluded.
Positivity rate equal to 0% on Day 2 was carried forward to Day 3 if Day 3 rate was not reported.
ND= There were no patients available with detectable parasitaemia in this category so the OR could not be estimated. P-value = 1.000 for comparison with
DHA+PIP treatment (Fisher’s exact test). For the purpose of logistic model this treatment group was merged with all other treatments (not included in the
listed categories).
Das et al. Malaria Journal 2013, 12:125 Page 7 of 12
http://www.malariajournal.com/content/12/1/125
Table 3 Univariate risk factors for early parasitaemia positivity rates in Asia
Day 1 Day 2 Day 3
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Age 1.03 (0.95-1.12) 0.474 0.96 (0.89-1.02) 0.185 0.85 (0.79-0.92) <0.001
Loge parasitaemia 2.42 (1.58-3.70) <0.001 3.11 (1.86-5.20) <0.001 8.20 (3.97-16.97) <0.001
Year 0.98 (0.82-1.16) 0.789 0.99 (0.76-1.30) 0.959 1.43 (1.07-1.91) 0.015
Artemisinin derivative <0.001 0.904 0.231
Artemether 1.00 1.00 1.00
Artemisinin ND 1.45 (0.25-8.43) 0.676 ND
Artesunate 0.83 (0.68-1.01) 0.058 1.06 (0.72-1.56) 0.784 3.85 (0.73-20.30) 0.113
DHA 0.50 (0.40-0.62) <0.001 0.97 (0.63-1.50) 0.904 3.39 (0.59-19.59) 0.173
Treatment <0.001 0.778 0.592
DHA+PIP 1.00 1.00 1.00
AL 2.04 (1.62-2.57) <0.001 1.02 (0.66-1.57) 0.934 0.29 (0.05-1.67) 0.167
AS+MQ 1.64 (1.36-1.98) <0.001 1.09 (0.85-1.41) 0.487 1.16 (0.65-2.06) 0.620
AS+SP 0.46 (0.12-1.86) 0.279 0.09 (0.003-2.68) 0.166 ND
AS+AQ 0.66 (0.11-4.04) 0.654 0.45 (0.03-5.94) 0.547 2.28 (0.16-32.22) 0.543
AS alone ND 1.25 (0.64-2.45) 0.512 1.45 (0.59-3.54) 0.414
Only patients who received artemisinin derivative until Day 1 (2 or 3) are included for analysis of PPRday1 (2 or 3). Study arms with rectal artesunate are excluded.
Positivity rate equal to 0% on Day 2 was carried forward to Day 3 if Day 3 rate was not reported.
ND= There were no patient data available or patients with detectable parasitaemia in this category so the OR could not be estimated. P-value = 0.623 for comparison with
DHA+PIP treatment (Fisher’s exact test). For the purpose of logistic model this treatment group was merged with all other treatments (not included in the listed categories).
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parasitaemic during follow up decreased at Day 1 (64%
to 43%), Day 2 (10% to 4.6%) and Day 3 (1.2% to 0%).
However these changes, adjusted for confounding fac-
tors, were not statistically significant in the logistic re-
gression model. In contrast, in Asian studies the
median proportion of patients parasitaemic at Day 3
rose from 0.4% in 2000 to 2005 to 6.5% in 2006 to
2011. However after adjusting for confounding factors,Table 4 Multivariable risk factors for early parasitaemia posit
Day 1
Variable AOR (95% CI) P-value AOR
Age 0.99 (0.97-1.02) 0.689 1.02 (
Loge parasitaemia 1.76 (1.18-2.62) 0.005 1.59 (
Year 0.84 (0.73-0.96) 0.012 0.92 (
Treatment
DHA+PIP 1.00
AL 1.32 (1.02-1.71) 0.033 1.61 (
AS+MQ 1.22 (0.77-1.91) 0.398 2.04 (
AS+SP 0.74 (0.32-1.74) 0.495 1.91 (
AS+AQ 1.06 (0.76-1.46) 0.740 1.84 (
AS alone 0.55(0.12-2.50) 0.439 0.74 (
Only patients who received artemisinin derivative until Day 1 (2 or 3) are included f
Positivity rate equal to 0% on Day 2 was carried forward to Day 3 if Day 3 rate was
ND= There were no patient data available or patients with detectable parasitaemia
model this treatment group was merged with all other treatments (not included inand exclusion of Cambodian studies, these temporal
trends were no longer statistically significant.
Identifying areas of delayed parasite clearance
The parasite prevalence rates and 95% confidence intervals
are presented in the forest plots at Day 3 (Figures 6 and 7)
and at Day 2 (Additional files 6 and 7). Overall the median
proportion of patients remaining parasitaemic after three-
day regimens was 53.8% [range 3–95, IQR=30.5-69.2] ativity rates in Africa
Day 2 Day 3
(95% CI) P-value AOR (95% CI) P-value
0.98-1.06) 0.368 1.04 (0.97-1.12) 0.252
1.16-2.18) 0.004 3.01 (1.18-7.64) 0.021
0.79-1.07) 0.270 0.78 (0.62-0.97) 0.026
1.00 1.00
1.14-2.28) 0.007 5.03 (0.58 – 43.52) 0.143
0.84-4.94) 0.115 9.45(0.61-146.06.76) 0.108
1.16-3.14) 0.011 4.89 (0.50-47.34) 0.171
1.23-2.74) 0.003 4.98 (0.59-42.07) 0.141
0.28-1.97) 0.548 ND
or analysis of PPRday1 (2 or 3). Study arms with rectal artesunate are excluded.
not reported.
in this category so the OR could not be estimated. For the purpose of logistic
the listed categories).
Table 5 Multivariate logistic regression model for early
parasite response in Asia
Day 1
Variable AOR (95% CI) P-value
Age 1.08 (1.02-1.14) 0.008
Loge parasitaemia 2.65 (1.67-4.21) <0.001
Year 0.90 (0.81-0.99) 0.039
Treatment
DHA+PIP 1.00 -
AL 1.81 (1.42-2.31) <0.001
AS+MQ 1.40 (1.12-1.76) 0.003
AS+SP 2.23 (0.67-7.42) 0.192
AS+AQ 0.66 (0.28-1.56) 0.342
AS alone ND
Only patients who received artemisinin derivative until Day 1 are included in
the analysis of PPR1. Study arms with rectal artesunate are excluded.
ND= There were no patient data available.
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http://www.malariajournal.com/content/12/1/125Day 1, 6.7% [range 0–73, IQR=2-12.9] at Day 2 and 0.5%
[range 0–55, IQR=0-2.2] at Day 3. When studies from
Cambodia were excluded, the corresponding proportions
were 53.8% [range 3–95, IQR=30.5-69.2], 6.0% [range 0–
65.9, IQR=2-11.5] and 0 [range 0–12.6, IQR=0-2]. In 95%
of studies the proportion of patients with peripheral para-
sitaemia was <84% at Day 1, <34.5% at Day 2 and <6% at0 .1 .2 0 .1




Figure 6 Forest plots of Day 3 parasite positivity rates in Africa. Estim
order (most recent first). Heterogeneity between studies I2: AL = 63.4%; AS+Day 3. In comparison, the studies from Western Cambodia
reported median parasite positivity rates of 60% [range 48–
73] at Day 2 and 48% [range 22–55] at Day 3.
Among 153 treatment arms reporting parasite positiv-
ity rate at Day 3, nine (5.9%) recorded a PPRday3 of 10%
or higher. Of them, six treatment regimens were evalu-
ated in Western Cambodia and one study was of a
single dose of artesunate (see Additional file 8). In the
remaining two studies [18,19] patients were treated
with a three-day AS+AQ in Senegal and Indonesia and
with PPRday3 documented as 10% (95%CI =6.3-15.6%)
and 12.6% (95% CI=7.5-20.4%) respectively.Discussion
The emergence and spread of resistance to anti-malarial
drugs has proven to be a crucial factor undermining mal-
aria control programmes and global aspirations for the
elimination of malaria. Anti-malarial resistance has
emerged to nearly all established anti-malarial com-
pounds and is considered as inevitable for any drugs that
are in common use and deployed widely. The conse-
quences of anti-malarial drug resistance are huge and are
associated with greater malaria attributable morbidity
and mortality. The use of ACT was designed to combat
anti-malarial drug resistance, increasing the treatment ef-
ficacy against even the most multidrug resistant isolates,.2 0 .1 .2
.2
e Rate on Day 3
odiaquine Artesunate+Mefloquine
aquine
ates and 95% CI are shown by treatment, sorted by year in descending
AQ = 75.5%; AS+MQ = 35.1%; AS+SP = 52.1%; PIP+DHA = 0.0%.
0 .1 .2 0 .1 .2 0 .1 .2 .3 .4 .5 .6 .7
0 .1 .2 0 .1 .2
Parasite Prevalence Rate on Day 3
Artemether-Lumefantrine Artesunate-Amodiaquine Artesunate+Mefloquine
Artesunate+SP DHA-Piperaquine
Figure 7 Forest plots of Day 3 parasite positivity rates in Asia. Estimates and 95% CI are shown by treatment, sorted by year in descending
order (most recent first). Heterogeneity between studies I2: AL = 0.0%; AS+AQ = 93.0%; AS+MQ = 88.0%; AS+SP = NA; PIP+DHA = 44.9%.
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preventing the emergence of de novo resistance. Over the
last decade more than 80 countries have adopted ACT as
a key component of national anti-malarial guidelines.
However, this strategy is now under threat with reports
of declining artemisinin efficacy against P. falciparum in-
fection. The first documentation of declining susceptibil-
ity came from Pailin in western Cambodia, and has now
been confirmed on the western border of Thailand, and
Vietnam [3,4,6]. The threat of an escalation to high-
grade artemisinin resistance spreading throughout the
malaria-endemic world is alarming and demands imme-
diate action to contain potential hotspots and retard the
spread of resistant parasites to new areas. To counter this
threat, WHO launched a coordinated plan outlined in
the Global Plan for Artemisinin Resistance Containment
(GPARC), which proposed an international commitment
to both accelerate malaria control efforts and implement
a number of additional activities [13].
The hallmark of declining artemisinin efficacy is a
delay in the early parasite clearance times. Prolonged
parasite clearance increases the risk of gametocyte car-
riage and thus transmission potential, as well as increas-
ing parasite exposure to the partner drug and thus the
risk of selecting for further drug-resistant isolates. The
assessment of therapeutic clinical response, particularly
the early parasite positivity rate has been identified as acrucial part of drug efficacy monitoring for artemisinin
resistance, but its interpretation is vulnerable to a num-
ber of confounding factors [20,21]. Novel approaches to
quantify the therapeutic efficacy have attempted to over-
come this by frequent blood film examination (at least
eight-hourly) and analysis of the slope of the parasit-
aemia clearance profiles [9]. Although such studies are
now being conducted prospectively by research groups,
their application is a significant change from current
in vivo protocols for uncomplicated malaria which have
derived the early parasite clearance mostly from once-
daily sampling. Simplified sampling strategies, although
less precise, have the advantage of being adopted across
a wider geographical area and logistical framework. Fur-
thermore, a system that is compatible with current pro-
tocols permits the analysis of data that has already been
gathered, to be re-examined to identify potential hot
spots of emerging artemisinin resistance. Monitoring of
the Day 3 parasite positivity rate has been proposed as a
simple, robust surveillance tool, with the rationale that
this crude test could identify sites warranting further
more detailed clinical investigation [12]. However, the
sensitivity, specificity and ultimate utility of such an ap-
proach will depend upon the threshold chosen to signal
a poor outcome and acknowledgement for the host,
parasite and drug factors that can either mask declining
susceptibility to artemisinin or give rise to false alarm.
Das et al. Malaria Journal 2013, 12:125 Page 11 of 12
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recent literature of clinical studies of artemisinin deriv-
atives in order to quantify the distribution of parasite
clearance times and the cofactors underlying these. Im-
portant variations are apparent in the design and
methodology of ACT clinical drug trials, indicative on
the rationale of the study, local epidemiology, as well
as logistical and funding constraints. In particular
microcopy protocols can vary considerably, and al-
though standardised quantification of thick and thin
films are crucial details of their underlying methodolo-
gies are rarely presented. Furthermore there were sig-
nificant differences in both the age of inclusion and
baseline parasitaemia, both of which are critical to the
speed of parasite clearance [12].
Although almost two thirds of studies reviewed in
this analysis, reported details on the early parasito-
logical response, these were reported inconsistently
with only 40% providing parasite positivity rates on
Day 2 and 37% on Day 3. Furthermore, 13% (n=28)
of these data points were estimated from figures
presented to depict parasitological response rather
than the text itself. From the data available, 91% of
patients had cleared their parasitaemia within two
days and 97.9% within three days, however there was
marked heterogeneity in clearance rates between
studies and regions (highlighted in Figures 6 and 7).
Several important confounding factors were identi-
fied. As expected, baseline parasitaemia was major
risk factor for patent parasitaemia particularly on
Day 3. Parasite positivity rates over the first day of
treatment were also significantly higher in children
than adults, although this was only apparent in Asian
studies where a greater spectrum of age groups was
recruited. After controlling for these factors, parasite
positivity rates varied considerably with the treatment
regimen administered, short course treatments being
associated with two- to six-fold higher rates of parasitaemia
at Day 2 and Day 3. Even when the analysis was restricted
to three-day regimens, the differences in parasite positivity
rates remained, with DHA-piperaquine associated with
significantly greater clearance than AL and AS+MQ (see
Tables 2 and 3).
Over the last decade the analysis of temporal trends
in parasite clearance reveal a significant increase in
the proportion of patients remaining parasitaemic at
Day 3 in Asia, however this was mostly accounted for
by the recent Cambodian studies which were clear
outliers. Outside of Cambodia no significant trend
was apparent. Conversely in Africa, the parasite posi-
tivity rate was noted to decrease over the decade at
each day of follow up, although this was mostly attrib-
utable to variation in the age of the patients and base-
line parasitaemia and was not apparent in multivariableanalysis. After excluding Cambodian studies, thresh-
olds expected to be achieved in 95% of clinical studies
could be estimated as a parasite positivity rates less
than 84% at Day 1, less than 35% at Day 2 and less
than 6% at Day 3. The current threshold for alerting
for a potential decline with artemisinin resistance has
been proposed as a PPR on Day 3 of greater than
10%, well above the 95th percentile. Using this defin-
ition, nine outliers were identified, six of which were
from the Pailin region, the epicentre for emerging ar-
temisinin resistance in Cambodia and one of which
was a short-course regimen. Of the remaining two
studies, one by Asih et al. from Indonesia conducted
in 2005 to 2006, combined PCR positivity with mi-
croscopy, which may have accounted for higher than
expected proportion of patients parasitaemic on Day
3 [19]. The remaining trial arm in a study by Adjuik
et al. was conducted in Senegal, although the Day 3
value was derived from a figure rather than actual
data [18], (see Additional file 8).
The present analysis relies on aggregated data col-
lected mostly from studies with once daily sampling.
The specificity of the 10% Day 3 PPR cut off in
detecting areas of declining artemisinin efficacy could
be estimated at 67%, assuming that the two studies
from Senegal and Indonesia was false positives. How-
ever it was not possible to determine the sensitivity of
this clinical marker particularly for detecting early in-
dications of emerging resistance. From the data
presented here and previous analyses it is clear that
the interpretation of simple measures of parasite
clearance are highly vulnerable to host, parasite and
drug factors, all of which vary significantly with het-
erogeneous study designs. Standardization of method-
ology, unified approaches for reporting, and the
application of more stringent inclusion and exclusion
enrolment criteria may go some way to controlling for
these. The WHO malaria guidelines on monitoring
in vivo drug resistance are regularly reviewed and
updated and are crucial in encouraging a standardized
approach to global drug resistance monitoring [10].
Complementary pooled analyses of individual level data
allow multivariate analysis, which increase the power to
identify locations of outlying studies that defy what has
historically been an extremely rapid parasitological re-
sponse. Current efforts by the WorldWide Antimalarial
Resistance Network (WWARN) are directed at facilitat-
ing such approaches, using subject-level data and
standardizing analytical outputs, ensuring that relevant
and validated data can be explored controlling for
confounding factors. Such endeavours are of critical
importance in building strong collaborative commit-
ments from the global malaria community to tackle a
major public health threat.
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